Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (2017 - 2025)

Historic Shares Outstanding for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $94.5 million.

  • Crinetics Pharmaceuticals' Shares Outstanding rose 1695.55% to $94.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.5 million, marking a year-over-year increase of 1695.55%. This contributed to the annual value of $92.9 million for FY2024, which is 3630.51% up from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Shares Outstanding stood at $94.5 million, which was up 1695.55% from $94.1 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Shares Outstanding peaked at $94.5 million during Q3 2025, and registered a low of $4.8 million during Q1 2022.
  • For the 5-year period, Crinetics Pharmaceuticals' Shares Outstanding averaged around $62.1 million, with its median value being $54.7 million (2023).
  • Its Shares Outstanding has fluctuated over the past 5 years, first plummeted by 8552.26% in 2022, then surged by 102949.79% in 2023.
  • Crinetics Pharmaceuticals' Shares Outstanding (Quarter) stood at $47.6 million in 2021, then rose by 13.19% to $53.9 million in 2022, then grew by 26.54% to $68.2 million in 2023, then surged by 36.31% to $92.9 million in 2024, then grew by 1.75% to $94.5 million in 2025.
  • Its Shares Outstanding was $94.5 million in Q3 2025, compared to $94.1 million in Q2 2025 and $93.5 million in Q1 2025.